3345 COMBI-v: health-related quality of life (HRQoL) impact of the combination of dabrafenib and trametinib (D+T) vs vemurafenib (V) in patients with BRAF V600 metastatic melanoma (MM)
Jean‐Jacques Grob(Aix-Marseille Université), Caroline Robert(Institut Gustave Roussy), Pengfei Sun(Shenzhen University Health Science Center), Kamil Drucis(Apple (Israel)), Jacob Schachter, Mayur M. Amonkar(GlaxoSmithKline (United States)), Andrzej Maćkiewicz(Poznan University of Medical Sciences), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), M. Lichinitser(Apple (Israel)), E. Levchenko(Research Medical Center), Axel Hauschild(University Hospital Schleswig-Holstein), Florent Grange(Hôpital Lyon Sud), Georgina V. Long(The University of Sydney), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Bijoyesh Mookerjee(Novartis (United States)), Bogusława Karaszewska(State University of Applied Sciences in Konin), Reinhard Dummer(University Hospital of Zurich), Diane Opatt McDowell(GlaxoSmithKline (United States)), D. Stroiakovski(Moscow City Oncology Hospital №62), Pascal Wolter(KU Leuven)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k